When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mainly used to make the site work as you expect it to. The information does not directly identify you but can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. However, blocking some types of cookies may impact your experience of the site. You can find more information, including a detailed cookie explanation, on our Cookie Policy.
QP-Prostate®
Your advanced solution for prostate MRI based on Artificial Intelligence for automated prostate segmentation and lesion detection*.
Discover QP-Prostate®
Prostate cancer is the second most common cancer in men, representing a significant public health concern. While MRI scans are essential for early detection, the growing demand has surpassed the availability of radiology experts, with diagnostic delays and inconsistencies in interpretation as direct consequences. Only a minority of the medical community consistently follows PI-RADS v2.1 guidelines.
QP-Prostate introduces enhanced diagnostic capabilities, streamlining radiologists’ workflows by automatically ensuring compliance with PI-RADS v2.1 guidelines, accurately segmenting the prostate gland, and efficiently identifying suspicious lesions*. These advancements enable radiologists to provide faster and more accurate assessments, directly improving patient care.
Prostate segmentation & lesion detection
QP-Prostate’s AI algorithm achieves 88% accuracy in segmenting the prostate gland and seminal vesicles, highlighting High (orange) and Moderate (yellow) risk areas for clinically significant prostate cancer (csPCa). This precision supports PSA density calculations and fusion biopsy planning. Our advanced AI-driven lesion detection, utilizing biparametric input (T2W and DWI), efficiently identifies prostate cancer lesions, setting a new standard for accuracy, speed, and diagnostic precision.
Your AI solution for advanced prostate cancer detection
QP-Prostate: a set of enhanced diagnostic capabilities
AI-based automatic lesion detection*
Our AI algorithm, trained with pathology outcomes as ground truth, is designed to efficiently detect clinically significant prostate cancer lesions using biparametric inputs (T2w, DWI and ADC), outperforming competitors in detection rate and speed. These AI algorithms are intended to elevate radiologists’ diagnostic accuracy with automated detection of biopsy-proven, clinically significant prostate cancer lesions.
Precision in segmentation
QP-Prostate’s AI algorithm automatically identifies the prostate anatomy and segments the full prostate gland with market-leading performance (88% DSC1), as well as the seminal vesicles, to assist in PSA density calculations. The results can be directly exported for fusion biopsy procedures.
Quantitative analysis
QP-Prostate automatically verifies MRI acquisition protocol according to PI-RADSv2.1 guidelines, ensuring that radiologists work with high-quality MRI examinations from the start.
The platform provides spatially registered, motion corrected, synthesized b-1400s/mm2 DWI and ADC map series, offering rich quantitative diffusion information. This dataset empowers radiologists to analyze potentially cancerous lesions with confidence. For mpMRI studies, perfusion analysis (Ktrans, Kep, Ve maps) are automatically generated.
Cloud to PACS integration
All analysis outputs are directly sent back to the hospital PACS for their visualization without disrupting radiology workflows.
How does it work?
Efficient workflow, increased confidence.
Clinical cases using QP-Prostate
Case 1
Patient history:
66 years old male, with elevated history of prostate specific antigen (PSA)
Summary:
Case 2
Patient history:
Abnormal prostate exam nodule superior half of right prostate; firm. PSA of 31.3 ng/ml.
Summary:
Case 3
Patient history:
61 years old man with elevated PSA, benign prostatic hyperplasia with lower urinary tract symptoms; PSA of 8.63 ng/mL.
Summary:
Case 4
Patient history:
62 year old male with history of low-grade prostate cancer diagnosed with biopsy. Most recent PSA of 13.34 ng/mL increased compared to prior which measures 9.99 ng/mL.
Summary:
Changing the narrative in prostate diagnosis thanks to maximum accuracy in prostate MRI interpretation
In short, QP-Prostate leverages advanced artificial intelligence image processing techniques to offer a state-of-the-art approach to prostate MRI interpretation. This image processing software is compatible with standard workstations and allows for the visualization and analysis of DICOM data by qualified professionals.
Developed by Quibim, QP-Prostate excels in automating the segmentation of critical prostate regions, including the transition zone, peripheral zone and seminal vesicles. By streamlining these complex processes, the software not only aids in the interpretation of prostate MRI images, but also enables more accurate diagnoses. This combination of sophisticated AI-based analysis and user-friendly implementation makes QP-Prostate an invaluable tool in the hands of healthcare professionals, ensuring better patient outcomes through more reliable and detailed assessments.
References
-
Jimenez-Pastor A, et al. Eur Radiol. 2023;33(7):5087-5096.
-
Sánchez Iglesias Á, et al. Cancers (Basel). 2023;15(16):4163.
*In the US: Lesion detection functionality pending 510(k), not available for sale within the United States
**Pilot study conducted in 2023 at Massachussets General Hospital.